| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |